SCHEDULE: State Street Reports 5.6% Stake in Intellia Therapeutics

Sentiment:

Beneficial Ownership Filing


State Street Corporation has disclosed a beneficial ownership of 5.6% in Intellia Therapeutics Inc. as of September 30, 2026.

Summary

  • State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 7,809,060 shares of Intellia Therapeutics Inc. common stock.
  • This ownership represents 5.6% of the class of securities.
  • The filing date is November 9, 2026, and the event date requiring the filing was September 30, 2026.
  • State Street Corporation holds shared power to vote and dispose of these shares.
  • The filing is made under Rule 13d-1(b) and State Street Corporation is identified as a 'HC' (likely meaning Holding Company or similar financial institution) type of reporting person.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a passive ownership stake without new strategic information or significant changes in holdings.

Positives

  • State Street Corporation's investment indicates confidence in Intellia Therapeutics' long-term prospects, as it is a significant institutional holder.
  • The passive nature of the filing suggests State Street is not seeking to influence control, which can be viewed positively by existing management.

Negatives

  • The filing does not provide any new strategic insights or positive operational updates from Intellia Therapeutics itself, only reporting on an existing institutional holding.
  • A 5.6% stake, while significant, does not represent a controlling interest and could be subject to change.

Risks

  • Potential for future changes in State Street's holdings, which could impact Intellia Therapeutics' stock price if a large block is sold.
  • The filing is a snapshot as of September 30, 2026, and current holdings may differ.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Intellia Therapeutics.

Management Comments

  • State Street Corporation certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional ownership, particularly by large asset managers like State Street, is common in the biotechnology sector, reflecting investor interest in companies with potentially disruptive technologies like CRISPR gene editing.

Stakeholder Impact

  • Shareholders: The filing confirms a significant institutional investor, which can be a positive signal, but also implies potential for future stock sales by this holder.
  • Management: The passive nature of the filing suggests no immediate threat to control, allowing management to focus on operations.

Next Steps

  • Monitor future filings from State Street Corporation for any changes in its beneficial ownership of Intellia Therapeutics.
  • Observe Intellia Therapeutics' own SEC filings for operational and financial updates.

Key Dates

DateDescription
2026-09-30Date of Event Which Requires Filing of this Statement
2026-11-09Date of Certification and Signature

Keywords

Intellia Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, CRISPR, Gene Editing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.